Insider · CIK 0001781450
Dror Bashan
Files at PLX (Protalix BioTherapeutics, Inc.). First filing Dec 23, 2025, latest Dec 23, 2025.
Dror Bashan files SEC Form 4 as CEO, president and director at PLX (Protalix BioTherapeutics, Inc.). Since Dec 23, 2025, Dror Bashan has reported 1 open-market buy worth $101k and 0 open-market sells worth $0, the latest filed on Dec 23, 2025.
A track record needs three past buys with six months of prices behind them; Dror Bashan has 0, so none is measured yet.
The newest scored trade: bought $101k of PLX on Dec 19, 2025, filed Dec 23, 2025, scored 41 (moderate). In the last 12 months: 1 buy worth $101k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PLX: Protalix BioTherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | PLXbuy Protalix BioTherapeutics, Inc. | $101k 56,000 shares | +42% | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +320,000 | $0.00 | $0 | 320,000 | 39 d ago |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +160,000 | $0.00 | $0 | 160,000 | 39 d ago |
| Dec 19, 2025 | PLX Protalix BioTherapeutics, Inc. | POpen-market purchase Common Stock | +56,000 | $1.81 | $101k | 188,516 | Dec 23, 2025 |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Common Stockindirect: By Trust | +195,000 | - | - | 2,344,418 | Sep 4, 2025 |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +340,000 | $0.00 | $0 | 340,000 | Sep 4, 2025 |
Questions about Dror Bashan
Answered from the filings on this page, as of the latest one.
Is Dror Bashan buying or selling?
In the last 12 months Dror Bashan reported 1 open-market buy worth $101k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $101k of PLX on Dec 19, 2025. Grants, option exercises and tax withholding are not counted.
How did Dror Bashan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dror Bashan has 0.
Where does Dror Bashan file Form 4?
Dror Bashan has filed Form 4 at PLX (Protalix BioTherapeutics, Inc.) as PRESIDENT AND CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.